Clinical trials sponsored by Daiichi Sankyo

Phase breakdown

Conditions studied

Recruiting trials led by Daiichi Sankyo

• A Study of Bempedoic Acid or Its Single-pill Combination Therapy With Ezetimibe in Patients With Primary Hypercholesterolaemia or Mixed Dyslipidaemia
  NCT07206472 · Phase: Not specified · Ages: 18 Years and older · Sex: All (male and female) · 23 locations
• A Study of DS9051b in Participants With Advanced or Metastatic Adrenocortical Carcinoma and Metastatic Castration-resistant Prostate Cancer
  NCT07189403 · Phase: Phase 1 · Ages: 18 Years and older · Sex: All (male and female) · 6 locations
• A Study of HER3-DXd in Subjects With Locally Advanced or Metastatic Solid Tumors
  NCT06172478 · Phase: Phase 2 · Ages: 18 Years and older · Sex: All (male and female) · 90 locations
• A Study of I-DXd in Combination With Atezolizumab With or Without Carboplatin as First-Line Induction or Maintenance in Subjects With Extensive Stage-Small Cell Lung Cancer (IDeate-Lung03)
  NCT06362252 · Phase: Phase 1, Phase 2 · Ages: 18 Years and older · Sex: All (male and female) · 58 locations
• A Study of Ifinatamab Deruxtecan Versus Treatment of Physician's Choice in Subjects With Relapsed Small Cell Lung Cancer
  NCT06203210 · Phase: Phase 3 · Ages: 18 Years and older · Sex: All (male and female) · 229 locations
• A Study of Valemetostat (DS-3201b) in Combination With Darolutamide in Metastatic Castration Resistant Prostate Cancer (mCRPC)
  NCT07244341 · Phase: Phase 1 · Ages: 18 Years and older · Sex: Male · 19 locations
• A Study to Assess the Effectiveness of Trastuzumab Deruxtecan in Chinese Breast Cancer Patients (REFRESH)
  NCT06210776 · Phase: Not specified · Ages: 18 Years and older · Sex: All (male and female) · 54 locations
• A Study to Evaluate the Efficacy and Safety of Ifinatamab Deruxtecan (I-DXd) in Subjects With Recurrent or Metastatic Solid Tumors (IDeate-PanTumor02)
  NCT06330064 · Phase: Phase 1, Phase 2 · Ages: 18 Years and older · Sex: All (male and female) · 120 locations
• Clinical Effectiveness and Safety of Trastuzumab Deruxtecan (T-DXd) in Chinese Patients With HER2m NSCLC (RERUN)
  NCT06809764 · Phase: Not specified · Ages: 18 Years and older · Sex: All (male and female) · 36 locations

Common questions

How many trials is Daiichi Sankyo recruiting for?

Daiichi Sankyo is the lead sponsor of 9 recruiting trials.

Is this list complete?

No. For the full record, search ClinicalTrials.gov.